Faculty

Marco Ruella, MD

Associate Professor of Medicine (Hematology-Oncology)

Department: Medicine

Graduate Group Affiliations

Contact information

South Tower 8-112
Perelman Center for Advanced Medicine
3400 Civic Center Blvd
Philadelphia, PA 191004

Office: 215-746-4880
Fax: 215-573-3638
Lab: 215-573-8538

Email:
mruella@upenn.edu

Publications

Search PubMed for articles

Education:
MD (Medical Degree)
University of Torino, Italy , 2007.

Links
Search PubMed for articles
Academia.edu
LinkedIn
Twitter
Research Gate
Ruella Lab Website
Institute for Immunology
Google Scholar

Permanent link

> Perelman School of Medicine > Faculty > Details

Description of Clinical Expertise

Dr. Ruella treat patients affected by hematological cancers and specializes in immunotherapy approaches.

Description of Research Expertise

Dr. Ruella's laboratory focuses on the mechanisms of relapse after chimeric antigen receptor T cell (CART) immunotherapies with the goal of rationally design innovative combined immunotherapies for relapsing/refractory leukemia and lymphoma.

Dr. Marco Ruella obtained his medical degree with high honors and completed his specialization in clinical hematology at the University of Torino, Italy. He was attending physician at the Hematology and Cell Therapy Division of the Mauriziano Hospital and was an Instructor at the Biotechnology School at the University of Torino. From late 2012, he was a Post-doctoral Fellow, and then an Instructor at the University of Pennsylvania in the Center for Cellular immunotherapies (Drs. June and Gill). From 2017 to 2018 he served as Associate Director of Dr. June’s laboratory. In 2018, Dr. Ruella was appointed Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies and Scientific Director of the Lymphoma Program at the Hospital of the University of Pennsylvania. Dr. Ruella was awarded many awards and honors, including the inaugural SITC EMD-Serono Cancer Immunotherapy Clinical Fellowship (2014), the AACR-BMS Oncology Fellowship in Clinical Cancer Research (2015), the ASH Scholar Award (2016), a NIH K99-R00 award (2017), the “Paola Campese” Award Leukemia Research (2017), the Cancer Support Community Award (2018), the 2018 ASH Joanne Levy, MD, Memorial Award for Outstanding Achievement, the Gilead Sciences Research Scholar in Hematology/Oncology and the Gabrielle’s Angel Foundation Award (2020), and the Leukemia and Lymphoma Society, Translational Research Program (2021). Dr. Ruella is the author of numerous peer-reviewed publications on targeted immunotherapies for hematological cancers and is an inventor in several patents on CART therapy and the Scientific Founder of viTToria biotherapeutics.

Selected Publications

Knoedler L, Herfeld K, Schaefer DA, Diatta F, Clune J, Evans B, Seu M, Kim BS, Alfertshofer M, Schaschinger T, Iske J, Knoedler S, Lellouch AG, Jeljeli M, Carturan A, Ruella M, Heiland M, Poeck H, Perl M, Pomahac B, Kauke-Navarro M.: CAR-T cell therapy and reconstructive oncologic surgery in peripheral solid tumors-A narrative review. Cell Rep Med 6(8), Aug 2025 Notes: doi: 10.1016/j.xcrm.2025.102240.

Shukla D, Manne S, Jiang S, Ruella M, Wherry EJ, Riley JL. : Optimal pairing of binder and co-stimulatory domains improves dual CART cell efficacy. Mol Ther. Aug 2025 Notes: doi: 10.1016/j.ymthe.2025.08.002.

Grzywa TM, Neeser A, Ramasubramanian R, Romanov A, Tannir R, Mehta NK, Cossette B, Morgan DM, Goncalves B, Sukaj I, Bergaggio E, Kadauke S, Myers RM, Paruzzo L, Ghilardi G, Cozzone A, Schuster SJ, Frey N, Zhang L, Yousefpour P, Abraham W, Suh H, Ruella M, Grupp SA, Chiarle R, Wittrup KD, Ma L, Irvine DJ. : Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells. Nat Biomed Eng. Aug 2025 Notes: doi: 10.1038/s41551-025-01470-0.

Guruprasad P, Ramasubramanian R, Nason S, Carturan A, Liu S, Paruzzo L, Hornet V, Plesset J, Patel RP, Bhoj V, Beatty GL, Ruella M. Manufacturing of CRISPR-edited primary mouse CAR T cells for cancer immunotherapy. : Manufacturing of CRISPR-edited primary mouse CAR T cells for cancer immunotherapy. Nat Protoc. July 2025 Notes: doi: 10.1038/s41596-025-01208-x.

Lϋӧnd F, Whalen J, Song Y, Schriefer K, Newcombe R, Orlando EJ, Choi SM, Ruella M, Fraietta JA, Schuster SJ, Brogdon JL, Niederst MJ, Treanor LM.: DLBCL cells emerge post CD19 CAR-T with cross-antigen resistance and a gene signature predictive of clinical CAR-T response. Blood Cancer Discov. Jun 2025 Notes: doi: 10.1158/2643-3230.BCD-24-0176.

Sullivan RJ, Cillo AR, Ferris RL, Jenkins RW, Kluger HM, Kok M, Lipson EJ, Paruzzo L, Redmond WL, Ruella M, Schalper KA, Thommen DS, Tolley K, Yarchoan M, Garnett-Benson C. : SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy. J Immunother Cancer. June 2025 Notes: doi: 10.1136/jitc-2025-011929.

Lϋӧnd F, Whalen J, Song Y, Schriefer K, Newcombe R, Orlando EJ, Choi SM, Ruella M, Fraietta JA, Schuster SJ, Brogdon JL, Niederst MJ, Treanor LM.: DLBCL cells emerge post CD19 CAR-T with cross-antigen resistance and a gene signature predictive of clinical CAR-T response. Blood Cancer Discov. June 2025 Notes: doi: 10.1158/2643-3230.BCD-24-0176.

Monette A, Aguilar-Mahecha A, Altinmakas E, Angelos MG, Assad N, Batist G, Bommareddy PK, Bonilla DL, Borchers CH, Church SE, Ciliberto G, Cogdill AP, Fattore L, Hacohen N, Haris M, Lacasse V, Lie WR, Mehta A, Ruella M, Sater S, Spatz A, Taouli B, Tarhoni I, Gonzalez-Kozlova E, Tirosh I, Wang X, Gnjatic S. : The Society for Immunotherapy of Cancer Perspective on Liquid Biopsy- and Radiomics-Based Technologies for Immuno-oncology Biomarker Discovery and Application. Clin Cancer Res. 31(12): 2278-2293, June 2025 Notes: doi: 10.1158/1078-0432.CCR-24-3791.

Ahmed SO, El Fakih R, Kharfan-Dabaja MA, Syed F, Mufti G, Chabannon C, Rondelli D, Mohty M, Al Ahmari AA, Gauthier J, Ruella M, Perales MA, Hashmi S, Alfraih F, Ghorashian S, Alzahrani M, Abba Z, Koh M, Pasquini M, Ruggeri A, Garderet L, Albabtain A, Weisdorf D, Greinix H, Samarkandi H, Hamad N, Atsuta Y, Hamadani M, Hari P, Majhail NS, Greco R, Alzahrani H, Sureda A, Yakoub-Agha I, Alahmari AD, Niederwieser D, Aljurf M.: Setting up a Chimeric Antigen Receptor T Cell Therapy Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation. Transplant Cell Ther. May 2025 Notes: doi: 10.1016/j.jtct.2025.05.012.

Thomas Luo, Luca Paruzzo, Sandra P. Susanibar Adaniya, Alfred L. Garfall, Matthew Ho, Shivani Kapur, Ruella M, Edward Allen Stadtmauer, Federico Stella, Dan T. Vogl, Adam J. Waxman, and Adam D. Cohen. : Disease response at apheresis and association with long-term outcomes following CAR-T cells for relapsed/refractory multiple myeloma (RRMM). Journal of Clinical Oncology 43(16), May 2025 Notes: https://doi.org/10.1200/JCO.2025.43.16_suppl.7518.